H2SITE Raises 12,5M€ to Scale Membrane Reactor Breakthrough Technology
H2SITE, a deep-tech pioneer in on-site hydrogen (H2) production, announced today that it has raised 12,5 M€ in a Series A funding round led by Breakthrough Energy Ventures (BEV), with participation from Equinor Ventures, ENGIE New Ventures, TECNALIA and institutional investors from the Basque Country (Capital Riesgo País Vasco (EZTEN FCR) and Seed Capital Bizkaia (SCB)).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005760/en/
Membrane bundle for ammonia cracking reactor (Photo: H2SITE)
The funding will accelerate the scale up of H2SITE's integrated membrane reactor and membrane separation technologies to obtain fuel cell purity hydrogen from ammonia or methanol cracking, or enable hydrogen transportation in existing natural gas infrastructure. H2SITE will also increase its membrane manufacturing capabilities, operating a world unique membrane manufacturing plant in the North of Spain.
“While much focus is given to hydrogen generation cost reduction, less attention is given to reduction of hydrogen transport cost. Transporting hydrogen is a complex task, it being a small molecule that is difficult to contain. The current compression, storage, decompression, and transport solutions are both economically and environmentally inefficient”, says Andrés Galnares, H2SITE’s CEO.
TECNALIA, Spain’s largest private research center, and the Technical University of Eindhoven realized that 13 years ago and developed the advanced membrane reactors. They combine special membranes with one-process-step reactors to produce onsite, low-cost renewable hydrogen. ENGIE’s R&D entity CRIGEN contributed to the development of the commercial version of the reactor. Intellectual Property was transferred into the newly created H2SITE to commercialize the technology.
H2SITE has since developed these onsite hydrogen generation units. Double skin inorganic membranes with long lifespan, integrated into process units can both crack hydrogen carriers and separate the hydrogen from blends in natural gas infrastructure or purify it in dedicated hydrogen infrastructure.
“Hydrogen is a promising pathway to decarbonize many parts of the economy but transporting it remains one of the biggest challenges. H2SITE has developed a solution that solves the transportation issue and will change the game for how quickly hydrogen can be deployed in already established pipelines which in turn could save billions of dollars in infrastructure costs,” said Carmichael Roberts of Breakthrough Energy Ventures.
H2SITE has shown strong commercial traction in 2022 and has recently been awarded projects to transform ammonia into H2 for the bus fleet in Birmingham, England, biogas into H2 for hydrogen refueling stations in Spain and in France, as well as several separation projects from H2 / natural gas blends in the gas transport infrastructure that are under construction.
“As an early investor from the very beginning of H2SITE journey, ENGIE New Ventures showed its commitment to the development of a promising and versatile technology to scale up sustainable and efficient solutions for industry and mobility needs; this support materialized also through ENGIE developing some commercial projects in H2 refueling stations using H2SITE technology,” said Johann Boukhors, Managing Director of ENGIE New Ventures.
According to BNEF’s New Energy Outlook 2021, the “green scenario” will require 1300M tons of H2 to reach net zero. If only 10% will be separated or transported with H2 carriers at an average cost of 0,5USD/kg, the market size in 2050 will be over 50 billion USD/year in 2050. H2SITE makes it possible to have access to these separation costs as of today and will further reduce them in the future.
“Equinor has high ambitions for clean hydrogen and Equinor Ventures invests in technologies that support the development of novel hydrogen value chains,” says Gareth Burns, head of Equinor Ventures. “H2Site has developed innovative technologies enabling the use of existing natural gas infrastructure to bring clean hydrogen to end users. These solutions have a potential for direct application within Equinor’s future hydrogen projects and I look forward to seeing the technology further developed and deployed,” he adds.
“H2SITE is a unique combination of: excellent research, mostly funded by European Commission framework programs resulting in state-of-the-art membrane reactor technology developed by Tecnalia and TUe; a purposeful entrepreneurial “A-Team”; some of the best smart capital in the realm of decarbonization in the World, topped with strong public support from with the participation of the sovereign funds of the Basque region, EZTEN FCR and Biscay region, SCB in the funding round; resulting in a gazelle massively incorporating top talent and anchoring a regional supply chain. This is the type of deep tech venture building endeavor that Tecnalia Ventures fosters, aimed at unfolding the potential Europe has to lead the global decarbonization challenge,” said Asier Rufino, CEO Tecnalia Ventures and H2SITE Chairman.
“This investment by BEV-E is much needed. The hydrogen economy needs to take off and I believe investments such as the current one may indeed be one of the triggers we’re waiting for,” said Mariya Gabriel, European Commissioner for Innovation, Research, Culture, Education and Youth. “Facilitating hydrogen transport will be important to scale-it-up. This shows that public funds can be married with private funds successfully, as happened with BEV-E. Investments in the energy transition must however take place at an even faster pace if we want to succeed in our climate ambition.”
Breakthrough Energy Ventures Europe (BEV-E) was established by the European Commission, the European Investment Bank and Breakthrough Energy Ventures to invest in innovative European companies and bring radically new clean energy technologies to the market. It was established to support Europe's best clean energy entrepreneurs whose solutions can deliver significant and lasting reductions in greenhouse gas emissions—H2SITE and this investment in the company is an example of that.
European Investment Bank (EIB) Vice-President Ricardo Mourinho Félix said: “To meet the global climate and energy challenges, we must scale up investment for clean energy technologies. Together with our partners at the European Commission, we are supporting Breakthrough Energy Ventures Europe which is investing in European companies such as H2SITE to find innovative solutions that will put the world on track to net-zero emissions. Transporting green hydrogen from geographies with strong renewable energy resources to demand centres is an important part of the EU Hydrogen and decarbonisation strategy. At the EIB, we will continue to work with our partners and project promoters to support the clean energy transition in Europe and around the world.”
H2SITE is currently hiring in the Bilbao region. To learn more, follow H2SITE on LinkedIn.
About H2SITE
H2SITE is a deep-tech start-up that uses advanced membrane reactor technology to solve the hydrogen transport problem by converting hydrogen carriers with well-known supply chains and separating hydrogen gas blends into fuel cell purity hydrogen.
About Breakthrough Energy Ventures
Founded by Bill Gates and backed by many of the world’s top business leaders, BEV has raised more than $2 billion in committed capital to support cutting-edge companies that are leading the world to net-zero emissions. BEV is a purpose-built investment firm that is seeking to invest, launch and scale global companies that will eliminate GHG emissions throughout the economy as soon as possible. BEV seeks true breakthroughs and is committed to supporting these entrepreneurs and companies by bringing to bear a unique combination of technical, operational, market and policy expertise.
BEV is a part of Breakthrough Energy, a network of investment vehicles, philanthropic programs, policy advocacy and other activities committed to scaling the technologies we need to reach net-zero emissions by 2050. Visit www.breakthroughenergy.org to learn more.
About EQUINOR Ventures
Equinor Ventures is Equinor’s corporate capital venture fund dedicated to investing in attractive and ambitious early phase and growth companies. We believe that the innovation, creativity and agility of start-ups can drive change and transition towards a low carbon future.
About ENGIE New Ventures
ENGIE New Ventures (ENV) is the investment fund of ENGIE, Research & Innovation division, dedicated to innovative climate technology startups and the corporate venture capital arm of ENGIE, the global energy and services provider. ENGIE is committed to lead the energy revolution, towards a more decarbonized, decentralized, and digitized world. ENV makes minority investments in innovative start-ups bringing strategic value to the Group with a focus on both the current ecosystem and on future breakthrough technologies. Since 2014, investments have been made in more than 45 solutions in the cleantech sector. Investment thesis is now focused in particular on renewables, energy efficiency solutions and flexibility, green gases including hydrogen. ENV’s offices are represented in Paris, San Francisco, Singapore, Santiago and Tel Aviv.
About TECNALIA
TECNALIA is the largest applied research and technological development center in Spain, a European benchmark and member of the Basque Research and Technology Alliance. We work with companies and institutions to increase their competitiveness, quality of life of people and achieve sustainable growth. Its main areas of action are digital transformation, smart manufacturing, energy transition, sustainable mobility, urban ecosystem, circular economy and personalized health. (www.tecnalia.com)
Through TECNALIA Ventures, its deep tech venture builder, the center collaborates in the identification and deployment of deep tech business opportunities with commercialization potential, through the development of its technological asset’s incubation acceleration program. (www.tecnaliaventures.com)
About EZTEN FCR
EZTEN FCR is a venture capital fund managed by Gestión de Capital Riesgo del País Vasco, a company belonging to the SPRI Group-Basque Agency for Business Development.
EZTEN FCR invests in innovative Basque companies, especially in the areas of biosciences, advanced manufacturing, and clean energy, in order to promote their development.
About Seed Capital Bizkaia
Public Company attached to the Department of Economic Promotion of the Provincial Council of Bizkaia, intended for the administration and management of various financing instruments. Founded in 1989, Seed Capital Bizkaia, during more than 30 years of work, has always made a firm commitment to promoting innovation, social impact and the promotion and regeneration of the business fabric in Bizkaia.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005760/en/
Contact information
Media Contact – Andrés Galnares; andres.galnares@h2site.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
